Ionis Pharmaceuticals Inc
IONS Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$43.96
KIRA · Stoqly’s AI analyst, in plain words
- Ionis Pharmaceuticals Inc had $944M of revenue in fiscal 2025, up 33.8% on the year before. Over five years, revenue changed +5.3% a year on average.
- Its operating margin was −40.4%, up 26.9 pts: of every 100 in sales, about −40 is left after running the business.
- Ionis Pharmaceuticals Inc lost $381M in fiscal 2025.
- Free cash flow was −$320M in fiscal 2025, −33.9% of revenue.
- Ionis Pharmaceuticals Inc has $865M more cash than debt.
Market cap
$7.3B
P/E
—
Revenue
$944M
Net income
−$381M
Free cash flow
−$320M
Operating margin
−40.4%
Ionis Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
+33.8%
Yes. Sales grew 33.8% last year.
Does it make a profit?
−40.4%
No. It lost money last year.
Does profit turn into cash?
−33.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ionis Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- IONIS PHARMACEUTICALS INC
- CIK
- 0000874015
Ionis Pharmaceuticals Inc · IONS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $810M | $587M | $788M | $705M | $944M |
| Revenue growth | 11.1% | −27.5% | 34.1% | −10.5% | 33.8% |
| Gross margin | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Operating margin | −3.7% | −69.8% | −44.9% | −67.4% | −40.4% |
| Net income | −$28.6M | −$270M | −$366M | −$454M | −$381M |
| Net margin | −3.5% | −45.9% | −46.5% | −64.4% | −40.4% |
| Diluted EPS | −$0.20 | −$1.90 | −$2.56 | −$3.04 | −$2.38 |
| Cash | |||||
| Cash from operations | $30.8M | −$274M | −$308M | −$501M | −$269M |
| Capital expenditure | $12.0M | $15.7M | $23.8M | $45.3M | $51.4M |
| Free cash flow | $18.8M | −$290M | −$331M | −$546M | −$320M |
| FCF margin | 2.3% | −49.4% | −42.1% | −77.5% | −33.9% |
| Share buybacks | $0.0M | $0.0M | — | — | — |
| Share count change | 1.0% | 0.6% | 0.9% | 4.4% | 7.0% |
| Debt and strength | |||||
| Cash and short-term investments | $2.1B | $2.0B | $2.3B | $2.3B | $2.7B |
| Debt incl. finance leases | — | $1.2B | $1.3B | $1.3B | $1.8B |
| Shareholders' equity | $772M | $573M | $387M | $588M | $489M |
| Current ratio | 9.7x | 7.1x | 5.9x | 8.5x | 3.8x |
| Interest coverage | −3.2x | −50.5x | −27.9x | −28.0x | −22.1x |
| Returns and quality | |||||
| Return on equity | −3.8% | −40.1% | −76.3% | −93.1% | −70.8% |
| Return on tangible equity | −3.9% | −47.1% | −94.7% | −77.1% | −78.0% |
| Piotroski F-score | 6 | 0 | 4 | 2 | 3 |
| Altman Z'' | 4.2 | 2.3 | 2.2 | 1.8 | 1.1 |
Insiders bought, 12 months
$1.1M
1 insider
Insiders sold, 12 months
$133M
19 insiders
Of sales under plans
83%
$111M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ionis Pharmaceuticals Inc · IONS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $43.96 a share, the company is worth $7.3B.
Source: SEC EDGAR XBRL filings (CIK 0000874015). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.